Remix Therapeutics Selected for Late-Breaking Oral Presentation
Remix Therapeutics was selected to give a late-breaking oral presentation at the 38th EORTC-NCI-AACR Symposium.
Related stories
Microsoft Reportedly Seeks $25 Billion Through Bond Sale
Microsoft shares were up 0.8% premarket after a report that the company is seeking $25 billion through a bond sale.
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
BASF Publishes Q3 2026 Earnings Call Q&A Transcript
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
Giant Network Q3 Net Profit Rises 16.0% Year Over Year
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
Bending Spoons Raises $330 Million in Private Placement With Berkshire Hathaway
Bending Spoons raised $330 million in a private placement with Berkshire Hathaway.
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
Alnylam Pharmaceuticals Q3 2026 Earnings Call Begins
Alnylam Pharmaceuticals' quarterly earnings call has begun.
M impact | EQUITY | Oct 29, 2026, 12:28 PM UTC
China Citic Bank Q3 Net Profit Rises 4.60% Y/Y
M impact | EQUITY | Oct 29, 2026, 12:27 PM UTC